The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Challenges and Opportunities for the Application of Boron Clusters in Drug Design
Abstract
There are two branches in boron medicinal chemistry: the first focuses on single boron atom compounds, and the second utilizes boron clusters. Boron clusters and their heteroatom counterparts belong to the family of cage compounds. A subset of this extensive class of compounds includes dicarbadodecaboranes, which have the general formula C2B10H12, and their metal biscarboranyl complexes, metallacarboranes, with the formula [M(C2B10H12)2(-2)]. The unique properties of boron clusters have resulted in their utilization in applications such as in pharmacophores, as scaffolds in molecular construction, and as modulators of bioactive compounds. This Perspective presents an overview of the properties of boron clusters that are pertinent for drug discovery, recent applications in the design of various classes of drugs, and the potential use of boron clusters in the construction of new pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Carbaboranes as Pharmacophores: Properties, Synthesis, and Application Strategies
Scholz, M., & Hey-Hawkins, E. (2011) · Chemical Reviews · doi:10.1021/cr200038x · Cited by 797
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crépin, T., Zhou, H., Zhang, Y.-K., Hernandez, V., Akama, T., Baker, S. J., et al. (2007) · Science · doi:10.1126/science.1142189 · Cited by 631
Pathophysiology and Therapeutic Potential of Purinergic Signaling
Burnstock, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.5 · Cited by 611
Applications of Radiolabeled Boron Clusters to the Diagnosis and Treatment of Cancer
Hawthorne, M. F., & Maderna, A. (1999) · Chemical Reviews · doi:10.1021/cr980442h · Cited by 559
Three-Dimensional Aromaticity in Polyhedral Boranes and Related Molecules
King, R. B. (2001) · Chemical Reviews · doi:10.1021/cr000442t · Cited by 528
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Therapeutic Potential of Boron-Containing Compounds
Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V., & Xia, Y. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.71 · Cited by 373
π Aromaticity and Three‐Dimensional Aromaticity: Two sides of the Same Coin?
Poater, J., Solà, M., Viñas, C., & Teixidor, F. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201407359 · Cited by 315
Cígler, P., Kožíšek, M., Řezáčová, P., Brynda, J., Otwinowski, Z., Pokorná, J., Plešek, J., Grüner, B., Dolečková-Marešová, L., Máša, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507577102 · Cited by 310
Boron Chemicals in Diagnosis and Therapeutics
Das, B. C., Thapa, P., Karki, R., Schinke, C., Das, S., Kambhampati, S., Banerjee, S. K., Van Veldhuizen, P., Verma, A., Weiss, L. M., et al. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.38 · Cited by 279
The elements of life and medicines
Chellan, P., & Sadler, P. J. (2015) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2014.0182 · Cited by 274
Boron-containing inhibitors of synthetases
Baker, S. J., Tomsho, J. W., & Benkovic, S. J. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00131g · Cited by 256
Chiral Drugs: Chemistry and Biological Action
(2011) · Wiley eBooks · doi:10.1002/9781118075647 · Cited by 245
Hernandez, V., Crépin, T., Palencia, A., Cusack, S., Akama, T., Baker, S. J., Bu, W., Feng, L., Freund, Y. R., Liu, L., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02058-12 · Cited by 196
Ban, H. S., & Nakamura, H. (2015) · The Chemical Record · doi:10.1002/tcr.201402100 · Cited by 167
The First CNS-Active Carborane: A Novel P2X7 Receptor Antagonist with Antidepressant Activity
Wilkinson, S. M., Gunosewoyo, H., Barron, M. L., Boucher, A. A., McDonnell, M., Turner, P., Morrison, D. E., Bennett, M. R., McGregor, I. S., Rendina, L. M., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500054n · Cited by 157
Design of HIV Protease Inhibitors Based on Inorganic Polyhedral Metallacarboranes
Řezáčová, P., Pokorná, J., Brynda, J., Kožíšek, M., Cígler, P., Lepšı́k, M., Fanfrlík, J., Řezáč, J., Šašková, K. G., Sieglová, I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9011388 · Cited by 152
Hit-to-Lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists
Baxter, A., Bent, J., Bowers, K. C., Braddock, M., Brough, S., Fagura, M., Lawson, M., McInally, T., Mortimore, M., Robertson, M. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.034 · Cited by 124
Tiwari, R., Mahasenan, K. V., Pavlovicz, R. E., Li, C., & Tjarks, W. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900031y · Cited by 122
Kožíšek, M., Cígler, P., Lepšı́k, M., Fanfrlík, J., Řezáčová, P., Brynda, J., Pokorná, J., Plesek, J., Grüner, B., Šašková, K. G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002334 · Cited by 110
Carborane‐Based Carbonic Anhydrase Inhibitors
Brynda, J., Mäder, P., Šícha, V., Fábry, M., Poncová, K., Bakardiev, M., Grüner, B., Cígler, P., & Řezáčová, P. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307583 · Cited by 103
Identification of HSP60 as a Primary Target of o-Carboranylphenoxyacetanilide, an HIF-1α Inhibitor
Ban, H. S., Shimizu, K., Minegishi, H., & Nakamura, H. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104739t · Cited by 102
Nucleic acids and nucleosides containing carboranes
Lesnikowski, Z. J., Shi, J., & Schinazi, R. F. (1999) · Journal of Organometallic Chemistry · doi:10.1016/s0022-328x(99)00129-1 · Cited by 101
The role of purinergic receptors in stem cell differentiation
Kaebisch, C., Schipper, D., Babczyk, P., & Tobiasch, E. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.11.003 · Cited by 89
Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1α inhibitors
Shimizu, K., Maruyama, M., Yasui, Y., Minegishi, H., Ban, H. S., & Nakamura, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.037 · Cited by 66
Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1
Wang, R., Zhou, S.-S., & Li, S. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391606 · Cited by 66
Stavila, V., Her, J., Zhou, W., Hwang, S., Kim, C. S., Ottley, L. A. M., & Udovic, T. J. (2010) · Journal of Solid State Chemistry · doi:10.1016/j.jssc.2010.03.026 · Cited by 64
Receptor‐Mediated Uptake of Boron‐Rich Neuropeptide Y Analogues for Boron Neutron Capture Therapy
Ahrens, V. M., Frank, R., Boehnke, S., Schütz, C., Hampel, G., Iffland, D. S., Bings, N. H., Hey‐Hawkins, E., & Beck‐Sickinger, A. G. (2014) · ChemMedChem · doi:10.1002/cmdc.201402368 · Cited by 60
Carbaboranes as pharmacophores: Similarities and differences between aspirin and asborin
Scholz, M., Kaluđerović, G. N., Kommera, H., Paschke, R., Will, J., Sheldrick, W. S., & Hey‐Hawkins, E. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.030 · Cited by 57
Pecina, A., Lepšı́k, M., Řezáč, J., Brynda, J., Mäder, P., Řezáčová, P., Hobza, P., & Fanfrlík, J. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp410216m · Cited by 57
ortho-Carbaborane derivatives of indomethacin as cyclooxygenase (COX)-2 selective inhibitors
Scholz, M., Blobaum, A. L., Marnett, L. J., & Hey‐Hawkins, E. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.063 · Cited by 55
Specific inhibition of HIV-1 protease by boronated porphyrins
DeCamp, D. L., Babé, L. M., Salto, R., Lucich, J. L., Koo, M., Kahl, S. B., & Craik, C. S. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00096a020 · Cited by 54
Fischli, W., Leukart, O., & Schwyzer, R. (1977) · Helvetica Chimica Acta · doi:10.1002/hlca.19770600326 · Cited by 50
Bednarska, K., Olejniczak, A. B., Wojtczak, B. A., Sułowska, Z., & Lesnikowski, Z. J. (2010) · ChemMedChem · doi:10.1002/cmdc.201000075 · Cited by 48
Asborin Inhibits Aldo/Keto Reductase 1A1
Scholz, M., Steinhagen, M., Heiker, J. T., Beck‐Sickinger, A. G., & Hey‐Hawkins, E. (2010) · ChemMedChem · doi:10.1002/cmdc.201000368 · Cited by 37
Hofmann, S., Frank, R., Hey‐Hawkins, E., Beck‐Sickinger, A. G., & Schmidt, P. M. (2013) · Neuropeptides · doi:10.1016/j.npep.2012.12.001 · Cited by 34
Lipophilicity, Polarity, and Hydrophobicity
Caron, G., Ermondi, G., & Scherrer, R. A. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00135-8 · Cited by 29
Nakamura, H., Yasui, Y., Maruyama, M., Minegishi, H., Ban, H. S., & Sato, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.081 · Cited by 28
Minegishi, H., Matsukawa, T., & Nakamura, H. (2012) · ChemMedChem · doi:10.1002/cmdc.201200502 · Cited by 23
RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5
Bolger, G. B. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.08.003 · Cited by 19
Fujii, S., Ohta, K., Goto, T., Oda, A., Masuno, H., Endo, Y., & Kagechika, H. (2012) · MedChemComm · doi:10.1039/c2md00294a · Cited by 16
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Grams, R. J., Santos, W. L., Scorei, I. R., Abad-García, A., Rosenblum, C. A., Bita, A., Cerecetto, H., Viñas, C., & Soriano-Ursúa, M. A. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00663 · Cited by 377
New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies
Stockmann, P., Gozzi, M., Kuhnert, R., Sárosi, M. B., & Hey-Hawkins, E. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00197b · Cited by 317
Boron Chemistry for Medical Applications
Ali, F., S Hosmane, N., & Zhu, Y. (2020) · Molecules · doi:10.3390/molecules25040828 · Cited by 270
Boron in drug design: Recent advances in the development of new therapeutic agents
Fernandes, G. F. S., Denny, W. A., & Dos Santos, J. L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.092 · Cited by 269
Metadata
- Authors
- Leśnikowski, Z. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-05-10
- Volume
- 59
- Issue
- 17
- Pages
- 7738-7758
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2343107732
- Cited by
- 348
- References
- 44
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.